Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the "Rete Ematologica Lombarda"

Alfredo Molteni, Marta Riva, Annamaria Pellizzari, Lorenza Borin, Alessandra Freyre, Rosa Greco, Marta Ubezio, Massimo Bernardi, Alessio Fariciotti, Guido Nador, Michele Nichelatti, Emanuele Ravano, Enrica Morra

Research output: Contribution to journalArticlepeer-review

Abstract

To analyze the unpredicted event of hematological improvement (HI) during iron-chelation therapy (ICT), we reviewed a series of 53 myelodysplastic patients with transfusion dependency in a retrospective study involving 8 centers afferent to the "Rete Ematologica Lombarda". According to the IWG response criteria published in the year 2000, we observed erythroid responses in 19 patients (35.1%), 5 major (9.2%) and 14 minor (25.9%). In the assessable patients, platelet response was 8/13 (61%) and neutrophil response was 13/17 (76.4%). Only in patients with erythroid improvement, multilineage responses were observed. Apparently, patients with greater erythropoiesis dysfunction may take more advantage.

Original languageEnglish
Pages (from-to)1233-1240
Number of pages8
JournalLeukemia Research
Volume37
Issue number10
DOIs
Publication statusPublished - Oct 2013

Keywords

  • Hematological improvement
  • Iron-chelation therapy
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the "Rete Ematologica Lombarda"'. Together they form a unique fingerprint.

Cite this